계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Sio Gene Therapies
company
About
Sio Gene Therapies is a clinical-stage biopharmaceutical company.
- 101 - 250
Highlights
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $55M
- Industries
- Biopharma,Biotechnology,Neuroscience,Therapeutics
- Founded date
- Jan 1, 2014
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Sio Gene Therapies, formerly known as Axovant, is a clinical-stage company with a singular focus on pushing the boundaries of gene therapy to develop treatments for debilitating neurodegenerative diseases, including GM1 gangliosidosis, Tay-Sachs/Sandhoff disease, and Parkinson’s disease. Sio is leveraging its foundational scientific expertise built on decades of research, extensive collaborations with leading gene therapy institutes, and a flexible vector platform to liberate patients with debilitating diseases through the transformational power of gene therapies.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$55M
Sio Gene Therapies has raised a total of
$55M
in funding over 2 rounds. Their latest funding was raised on
Feb 3, 2017 from a Post-IPO Debt round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 3, 2017 | Post-IPO Debt | $55M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Sio Gene Therapies is funded by 1 investors.
Hercules Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Hercules Capital
|
— | Post-IPO Debt |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
